Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Recursion official investor newsroom · 行業原文收錄 · 來源發佈:Thu Oct 15 2026 12:45:47 GMT+0000 (Coordinated Universal Time) · 本站收錄:Thu Oct 15 2026 13:07:49 GMT+0000 (Coordinated Universal Time)
已保存的原文節選
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration October 15, 2026 at 8:45 AM EDT PDF Version Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027 Salt Lake City, UT , Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion
以上為帶出處的原文節選,完整內容請閱讀原始鏈接。自動收錄與主題分類不等於事實核驗。